Peptide therapeutics are increasingly used in the treatment of disease, but their
administration by injection reduces patient compliance and convenience, especially for …

OBJECTIVE—We have developed a novel platform for display and delivery of bioactive
peptides that links the biological properties of the peptide to the pharmacokinetic properties …

Diabetes mellitus is a major health problem with increasing prevalence at a global level. The
discovery of insulin in the early 1900s represented a major breakthrough in diabetes …

Aims To characterize the pharmacology of MEDI0382, a peptide dual agonist of glucagon
like peptide1 (GLP1) and glucagon receptors. Materials and methods MEDI0382 was …

Antidiabetic treatments aiming to reduce body weight are currently gaining increased
interest. Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist administered twice …

Peptide drugs targeting class B1 G-protein-coupled receptors (GPCRs) can treat multiple
diseases; however, there remains substantial interest in the development of orally delivered …

Abstract Glucagonlike peptide1 (GLP1) is secreted by intestinal Lcells following food
intake, and plays an important role in glucose homeostasis due to its stimulation of glucose …

Peptide drugs are an exciting class of pharmaceuticals for the treatment of a variety of
diseases; however, their short half-life dictates multiple and frequent injections causing …

Type 2 diabetes mellitus (T2DM) is increasing in global prevalence and is associated with
serious health problems (eg, cardiovascular disease). Various treatment options are …

Glucagon-like peptide-1 (GLP-1) has the ability to lower the blood glucose level, and its
regulatory functions make it an attractive therapeutic agent for the treatment of type 2 …